Author

Brandy N. Perkins

Johns Hopkins University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

Amy Elizabeth DezerniD· 2 shared Bogdan C. Paun· 2 shared Ivana GojoiD· 2 shared Linda M S ResariD· 2 shared Mark J. LevisiD· 2 shared Nour Sabiha NajiiD· 2 shared Styliani KaranikaiD· 2 shared Suman PauliD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Amy Elizabeth DezernORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML

Nour Sabiha Naji, Taha S. Ahmedna, J. David Peske, Xinghan Zeng, Brandy N. Perkins, Zanshé Thompson, Tushar D. Nichakawade, Bum Seok Lee, Evangeline Watson, Theodora Chatzilygeroudi, Li Luo, Bogdan C. Paun, Melanie Klausner, Yuju An, Teodora Supeanu, , Theodoros Karantanos

This paper develops an anti-CCRL2 antibody-drug conjugate (ADC) that shows potent cytotoxicity against high-risk MDS/AML cells without harming healthy hematopoietic cells.

bioRxiv · Aug 17, 2025 · PreprintCancer Biology

CCRL2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated TP53

Nour Sabiha Naji, Sergiu Paşca, Theodora Chatzilygeroudi, Pablo Toledano-Sanz, Joseph Cataquiz Rimando, Yashvi Hemani, Brandy N. Perkins, Xinghan Zeng, C. Conover Talbot, Bogdan C. Paun, Abdulmuez Abdulmalik, Chen Lossos, Tatianna R. Boronina, Ilias Sinanidis, Panagiotis Tsakiroglou, , Theodoros Karantanos

This study identifies CCRL2 as a driver of IFN-γ signaling in TP53-mutated AML with erythroid differentiation, linking it to disease progression and poor outcomes.

bioRxiv · Feb 21, 2025 · PreprintCancer Biology